ABSTRACT
In recent years, a myriad of biomaterials and associated biomedical technologies have been routinely used. These innovations have undoubtedly broadened the field of treatment, but they have also created many moral and ethical concerns. Aiming to become first to market, economically driven technological advancement in biomaterials has frequently resulted in ethical issues being readily ignored. Lax rules and a lack of supervision by institutions result in products that are not safe for patients can be openly sold, and there may also be products that are not fully licenced to enter the system. The science of biomaterials and implant design and performance is founded on well-known physics, chemistry, biology and physiology concepts. Responsible clinicians must be informed of the many biosafety elements of regularly used biomaterials, as well as guarantee that patients’ rights to nonmaleficence, beneficence and autonomy are protected. All healthcare professionals must be aware of the bioethical considerations related with these new materials and technologies in order to be better equipped to use them safely and confidently.
